Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leiner

This article was originally published in The Tan Sheet

Executive Summary

To launch private-label equivalent of Tums Ultra Strength tablets in SKUs of 36 and 72 in December under its Pharmacist Formula control brand. Also in December, the company will introduce 500 mg acetaminophen (72- and 100-count SKUs) and 200 mg ibuprofen (72- and 100-count SKUs) in senior-friendly Kwik Kap packaging. Leiner will add a private-label version of P&G's DayQuil sinus & congestion caplets (12 count) in January 1995 to its recently launched equivalent of DayQuil sinus & pain caplets (20 count). The company will debut a version of P&G's Vicks children's chewable DayQuil allergy in four-ounce bottles in January. In February, Leiner will launch a copy of Benadryl cold/allergy caplets (20 and 40 count) and a version of P&G's Pepto-Bismol caplets (40 count). Expected in December 1995 is Leiner's version of Kaopectate IB caplets in 6- and 12-count SKUs

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS083476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel